---
title: "Veradermics to present age-subgroup data from VDPHL01 male hair loss trial at AAD Innovation Academy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293029911.md"
description: "Veradermics presented age-subgroup data from the Phase 2/3 Study 302 of VDPHL01 for male pattern hair loss at the AAD Innovation Academy on July 16-17, 2026. The study enrolled over 500 males, comparing extended-release oral minoxidil against placebo. Key pipeline catalysts include expected topline results from Phase 3 male Study 304 in late 2026 and female Study 306 in early 2027."
datetime: "2026-07-17T11:30:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293029911.md)
  - [en](https://longbridge.com/en/news/293029911.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293029911.md)
generator: "portal-rs"
---

# Veradermics to present age-subgroup data from VDPHL01 male hair loss trial at AAD Innovation Academy

-   Veradermics flagged new age-based subgroup results from Phase 2⁄3 Study 302 of VDPHL01 in male pattern hair loss. \* Data were presented July 16, 2026, with an additional oral presentation scheduled July 17, 2026, at the AAD Innovation Academy. \* Study 302 enrolled over 500 males, testing an extended-release oral minoxidil formulation versus placebo in mild-to-moderate hair loss. \* Pipeline catalysts include expected topline results from Phase 3 male Study 304 in 2H 2026, female Study 306 in 1H 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260717016126) on July 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MANE.US](https://longbridge.com/en/quote/MANE.US.md)

## Related News & Research

- [Montanova Capital reports disposal of 750,000 Veradermics common shares worth $80.44 million](https://longbridge.com/en/news/296656843.md)
- [Veradermics CEO Reid Alexander Waldman disposes of common shares worth $7.24 million](https://longbridge.com/en/news/296284595.md)
- [Young female investors’ pots ‘nearly £4,600 bigger than those belonging to men’](https://longbridge.com/en/news/296154079.md)
- [Buy Rating Reaffirmed on Strong VDPHL01 Data and Catalyst-Rich Roadmap; Price Target Maintained at $164](https://longbridge.com/en/news/295697879.md)
- [Veradermics director John W. Childs disposes of USD 10.18 million in common shares](https://longbridge.com/en/news/295981158.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**